186 related articles for article (PubMed ID: 18772225)
1. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
Losasso C; Cretaio E; Fiorani P; D'Annessa I; Chillemi G; Benedetti P
Nucleic Acids Res; 2008 Oct; 36(17):5635-44. PubMed ID: 18772225
[TBL] [Abstract][Full Text] [Related]
2. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
3. Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.
Chillemi G; D'Annessa I; Fiorani P; Losasso C; Benedetti P; Desideri A
Nucleic Acids Res; 2008 Oct; 36(17):5645-51. PubMed ID: 18765473
[TBL] [Abstract][Full Text] [Related]
4. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
van der Merwe M; Bjornsti MA
J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711
[TBL] [Abstract][Full Text] [Related]
5. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
6. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
7. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
9. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
[TBL] [Abstract][Full Text] [Related]
10. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
Champoux JJ
Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
[TBL] [Abstract][Full Text] [Related]
11. Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants.
Sirikantaramas S; Yamazaki M; Saito K
Proc Natl Acad Sci U S A; 2008 May; 105(18):6782-6. PubMed ID: 18443285
[TBL] [Abstract][Full Text] [Related]
12. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
13. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
D'Annessa I; Tesauro C; Wang Z; Arnò B; Zuccaro L; Fiorani P; Desideri A
Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of topoisomerase I poisoning by a camptothecin analog.
Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
[TBL] [Abstract][Full Text] [Related]
16. The effect of camptothecin on topoisomerase I catalysis.
Christiansen K; Westergaard O
Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
[TBL] [Abstract][Full Text] [Related]
17. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
[No Abstract] [Full Text] [Related]
18. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
Scaldaferro S; Tinelli S; Borgnetto ME; Azzini A; Capranico G
Chem Biol; 2001 Sep; 8(9):871-81. PubMed ID: 11564555
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
20. The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.
Fiorani P; Chillemi G; Losasso C; Castelli S; Desideri A
Nucleic Acids Res; 2006; 34(18):5093-100. PubMed ID: 16990249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
